Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 30;10(13):2954.
doi: 10.3390/jcm10132954.

Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020

Fabien Taieb  1 , Khardiata Diallo Mbaye  2 , Billo Tall  1 , Ndèye Aïssatou Lakhe  2 , Cheikh Talla  1 , Daouda Thioub  2 , Amadou Moustapha Ndoye  1 , Daye Ka  2 , Aboubacry Gaye  1 , Viviane Marie-Pierre Cissé Diallo  2 , Ndongo Dia  1 , Pape Samba Ba  3 , Mamadou Cissé  1 , Moustapha Diop  3 , Cheikh Tidiane Diagne  1 , Louise Fortes  2   4 , Mamadou Diop  1 , Ndèye Maguette Fall  2   5 , Fatoumata Diène Sarr  1 , Margarite Diatta  1 , Mamadou Aliou Barry  1 , Aboubakar Sidikh Badiane  2   6 , Abdoulaye Seck  1 , Philippe Dubrous  1 , Ousmane Faye  1 , Inès Vigan-Womas  1 , Cheikh Loucoubar  1 , Amadou Alpha Sall  1 , Moussa Seydi  2
Affiliations

Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020

Fabien Taieb et al. J Clin Med. .

Abstract

As of today, little data is available on COVID-19 in African countries, where the case management relied mainly on a treatment by association between hydroxychloroquine (HCQ) and azithromycin (AZM). This study aimed to understand the main clinical outcomes of COVID-19 hospitalized patients in Senegal from March to October 20202. We described the clinical characteristics of patients and analysed clinical status (alive and discharged versus hospitalized or died) at 15 days after Isolation and Treatment Centres (ITC) admission among adult patients who received HCQ plus AZM and those who did not receive this combination. A total of 926 patients were included in this analysis. Six hundred seventy-four (674) (72.8%) patients received a combination of HCQ and AZM. Results showed that the proportion of patient discharge at D15 was significantly higher for patients receiving HCQ plus AZM (OR: 1.63, IC 95% (1.09-2.43)). Factors associated with a lower proportion of patients discharged alive were: age ≥ 60 years (OR: 0.55, IC 95% (0.36-0.83)), having of at least one pre-existing disorder (OR: 0.61, IC 95% (0.42-0.90)), and a high clinical risk at admission following NEWS score (OR: 0.49, IC 95% (0.28-0.83)). Few side effects were reported including 2 cases of cardiac rhythmic disorders in the HCQ and AZM group versus 13 in without HCQ + AZM. An improvement of clinical status at 15 days was found for patients exposed to HCQ plus AZM combination.

Keywords: SARS-CoV-2; Senegal; azithromycin; hydroxychloroquine; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of participants included in the Cohort study. HCQ: hydroxychloroquine; AZM: azithromycin.
Figure 2
Figure 2
Multivariate analysis of clinical status at D15.
See this image and copyright information in PMC

References

    1. WHO Novel Coronavirus–China 12 January 2020. [(accessed on 1 June 2020)]; Available online: http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/
    1. WHO WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19-11 March 2020. [(accessed on 1 June 2020)]; Available online: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re....
    1. SMoHaS, Coronavirus (COVID-19) Situation Dashboard. [(accessed on 30 October 2020)]; Available online: https://cartosantesen.maps.arcgis.com/apps/opsdashboard/index.html#/260c....
    1. Gautret P., Hoang V.T., Lagier J.-C., Raoult D. Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes. Int. J. Antimicrob. Agents. 2021;57 doi: 10.1016/j.ijantimicag.2020.106239. - DOI - PMC - PubMed
    1. Gautret P., Lagier J.C., Parola P., Hoang V.T., Meddeb L., Mailhe M., Doudier B., Courjon J., Giordanengo V., Vieira V.E., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents. 2020;56 doi: 10.1016/j.ijantimicag.2020.105949. - DOI - PMC - PubMed